
MaxQ-AI
Transforming healthcare by empowering physicians to provide ‘smarter care’ with enhanced clinical workflows.
USD | 2018 | 2019 | 2020 | 2021 | 2023 |
---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | 28 % | 22 % | - | - |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
MaxQ AI is a pioneering company in the field of artificial intelligence, deep learning, and machine vision, specifically focused on medical diagnostics. The company collaborates with world-class clinical partners to innovate at the intersection of clinical expertise and advanced AI technologies. MaxQ AI's core product leverages deep learning algorithms to analyze unstructured medical data, particularly in radiology, to provide unprecedented insights. The primary market for MaxQ AI includes hospitals, radiology departments, and healthcare providers in the USA and Europe. The business model revolves around deploying its AI solutions through major CT, AI ecosystem, and PACS (Picture Archiving and Communication System) channel partners. Revenue is generated through licensing fees, subscription models, and partnerships with healthcare institutions. MaxQ AI aims to improve the quality of patient care by enabling faster, more accurate diagnostics, which in turn can reduce healthcare costs and improve patient outcomes. The company's technology is particularly effective in increasing the detection of Intracranial Hemorrhages (ICH) and reducing missed diagnoses through near real-time triage, annotation, and notification systems.
Keywords: AI diagnostics, deep learning, machine vision, radiology, healthcare, medical data, ICH detection, clinical partners, PACS, cost reduction.